NCT06158815Completed
Investigation of the Effects of Proprioceptive Neuromuscular Facilitation Exercises in Patients With Myasthenia Gravis
Investigation of the Effects of Proprioceptive Neuromuscular Facilitation Exercises on Fatigue, Muscle Strength and Functional Parameters in Patients With Myasthenia Gravis
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to investigate of the effects of proprioceptive neuromuscular facilitation exercises on fatigue, muscle strength and functional parameters in patient with Myasthenia Gravis. The main questions it aims to answer are: * Do proprioceptive neuromuscular facilitation exercises reduce fatigue in patients with Myasthenia Gravis? * Do proprioceptive neuromuscular facilitation exercises increase muscle strength in patients with Myasthenia Gravis? * Do proprioceptive neuromuscular facilitation exercises improve functional parameters in patients with Myasthenia Gravis? * How well can patients with Myasthenia Gravis tolerate proprioceptive neuromuscular facilitation exercises? Participants will be divided into 2 groups as control group and exercise group with block randomization method. In this single-blind randomized controlled study, the participants in the control group will be placed on a waiting list without any intervention during the 6-week study period and at the end of the study, the interventions applied to the exercise group will be applied exactly the same. Proprioceptive neuromuscular facilitation exercises will be applied to the exercise group 3 days a week, 1 hour a day for 6 weeks. Individuals will be evaluated at the beginning and at the end of the study. Researchers will compare exercise and control group to see if there are effects of proprioceptive neuromuscular exercises patients with Myasthenia Gravis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 22 Nov 2023
- Start date
- 23 Nov 2023
- Primary completion date
- 9 Jul 2024
- Lead sponsor
- Hacettepe University
- Diseases
- Myasthenia gravis
- NCT number
- NCT06158815
What you commit to
- Study type: Interventional
- Participants enrolled: 23
- From 23 Nov 2023 to the primary completion date, 9 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having undergone pregnancy, birth or surgical operation in the last 6 months.
Other illness
- Having another cardiorespiratory, metabolic, systemic, rheumatological, orthopaedic and neurological disease (unstable and at a level that prevents participation in the exercise programme) in addition to Myasthenia Gravis
Other
- Having a cognitive problem or having a Mini Mental Test score below 24
- Change in the type and dose of medical treatment within the last 6 months
- Having a body mass index below 17 kg/m2 and above 30 kg/m2
- Having participated in any physiotherapy program any intervention study for the last 6 months
Who the study is looking for
- Volunteering to participate in the study
- Being between the ages of 18-65
- It must be confirmed by the Neurologist that the patient has been diagnosed with adult onset and Achr+ generalized Myasthenia Gravis and has been in a stable condition for the last 6 months.
- Being in class II or III according to the American Myasthenia Gravis Foundation Clinical Classification
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hacettepe University Faculty of Physical Therapy and Rehabilitation Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.